Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dynavax’ Heplisav Phase III Data Bolsters Hep B Seroprotection Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Long-term data from study comparing Heplisav to GSK's Engerix-B shows 100 percent seroprotection 50 weeks post-vaccination.

You may also be interested in...



Merck And Dynavax Pair Up For Heplisav

Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.

Merck And Dynavax Pair Up For Heplisav

Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.

Dynavax Licenses Coley’s Toll-Like Receptor Adjuvant For Hep B Vaccine Candidate Heplisav

BLA asking approval of one-month, two-dose vaccine regimen anticipated in second half of 2008.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel